10-Q: uniQure Reports Q1 2026 Results, Faces FDA Setback for Huntington's Drug

uniQure N.V. reported its first-quarter 2026 financial results, highlighting increased license revenues but also a significant regulatory hurdle for its lead Huntington's disease candidate, AMT-130.

Summary

• uniQure N.V. reported a net loss of $53.5 million for the first quarter ended March 31, 2026, an increase from the $43.6 million net loss in the same period of 2025.
• Total revenues increased to $3.6 million from $1.6 million in the prior year's quarter, primarily driven by license revenues from CSL Behring.
• Research and development (R&D) expenses decreased to $29.2 million from $36.1 million, while selling, general and administrative (SG&A) expenses significantly increased to $20.1 million from $10.9 million.
• The company's cash and cash equivalents and investment securities stood at $586.6 million as of March 31, 2026, with management projecting sufficient funding into the second half of 2029.
• A significant development is the FDA's feedback indicating that data from the Phase I/II studies of AMT-130 are unlikely to support a Biologics License Application (BLA) submission, recommending a prospective, randomized, double-blind, sham surgery-controlled study.
• The company plans to submit a Marketing Authorization Application for AMT-130 in the UK in the third quarter of 2026.
• Updated preliminary data for AMT-191 for Fabry disease showed dose-dependent elevations in -Gal A activity and durable increases, with all 11 dosed patients withdrawn from enzyme replacement therapy (ERT).
• Development of AMT-162 for amyotrophic lateral sclerosis (ALS) has been discontinued due to a dose-limiting toxicity and a related serious adverse event (SAE).
• The company entered into agreements to terminate its obligation to supply HEMGENIX and minimum purchase commitments under the Genezen CSA, with Genezen designated as CSL Behring's contract manufacturing organization.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative filing due to the significant FDA setback for AMT-130, the discontinuation of another program, and increased operating expenses, despite some positive clinical data and a strong cash position.

Positives

• License revenues increased to $3.6 million in Q1 2026 from $1.6 million in Q1 2025.
• AMT-130 Phase I/II studies showed a statistically significant 75% slowing of disease progression in high-dose patients as measured by cUHDRS at 36 months, meeting the primary endpoint.
• AMT-130 also demonstrated a statistically significant 60% slowing of disease progression as measured by TFC, meeting a key secondary endpoint.
• AMT-191 for Fabry disease showed durable, dose-dependent elevations in -Gal A activity, with all 11 dosed patients withdrawn from ERT.
• Cash and cash equivalents and investment securities totaled $586.6 million as of March 31, 2026, providing a projected runway into the second half of 2029.
• The company plans to submit a UK Marketing Authorization Application for AMT-130 in Q3 2026.

Negatives

• Net loss increased to $53.5 million in Q1 2026 from $43.6 million in Q1 2025.
• Selling, general and administrative expenses increased significantly by $9.2 million to $20.1 million in Q1 2026 compared to Q1 2025.
• The FDA has stated that data from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission, recommending a new prospective, randomized, double-blind, sham surgery-controlled study.
• Development of AMT-162 for SOD1-ALS has been discontinued due to a dose-limiting toxicity and a related SAE.
• Two patients in the mid-dose cohort of the AMT-191 trial experienced asymptomatic Grade 3 liver enzyme elevations, identified as dose-limiting toxicities, leading to a pause in further dosing.
• A class action lawsuit was filed in February 2026 related to alleged misleading statements concerning the AMT-130 Phase I/II study and BLA filing timing.

Risks

• The FDA's feedback on AMT-130 suggests a significant delay and increased cost for potential US market approval, requiring a new, large-scale clinical trial.
• The discontinuation of the AMT-162 program for SOD1-ALS represents a setback for that therapeutic area.
• The dose-limiting toxicities observed in the AMT-191 trial for Fabry disease could impact its future development.
• The company faces ongoing risks associated with the inherent uncertainties of gene therapy development, including clinical trial outcomes, regulatory approvals, and manufacturing.
• The class action lawsuit filed in February 2026 poses legal and financial risks.
• The company may require additional financing if it exhausts its current capital resources sooner than expected or if development costs exceed projections.

Future Outlook

uniQure projects that its current cash, cash equivalents, and investment securities will be sufficient to fund its projected operating expenses into the second half of 2029. This projection includes funding ongoing clinical trials for AMT-130, AMT-191, and AMT-260, as well as potential investments for late-stage development. However, the company acknowledges that actual expenditures may vary and additional funding may be required. The company is actively engaging with the FDA regarding AMT-130 and plans to submit a UK Marketing Authorization Application in Q3 2026.

Management Comments

• The FDA stated that it cannot agree that data from the Phase I/II studies of AMT-130 are sufficient to provide the primary evidence of effectiveness required to support a marketing application.
• The FDA strongly recommended we conduct a prospective, randomized, double-blind, sham surgery-controlled study for AMT-130.
• We intend to continue engaging with the FDA and have scheduled a Type B meeting with the agency in the second quarter of 2026.
• We plan to submit a UK Marketing Authorization Application for AMT-130 in the third quarter of 2026.
• We have decided to discontinue development of AMT-162.
• We believe that the consistently favorable results in functional, motor and cognitive endpoints at 36 months observed in the high-dose group, compared to the variable trends observed in the low-dose group, reflect a dose-dependent response to AMT-130.

Industry Context

StockSavvy.ai notes that uniQure's Q1 2026 results reflect the high-risk, high-reward nature of gene therapy development. The FDA's feedback on AMT-130 highlights the stringent requirements for regulatory approval in the US, often necessitating large, randomized controlled trials, which can be a significant hurdle for companies in this sector. The discontinuation of AMT-162 is also a common occurrence in early-stage gene therapy research where safety or efficacy signals do not meet expectations. The company's continued focus on AMT-130 and progress with AMT-191, despite setbacks, demonstrates a commitment to advancing its pipeline.

Comparison to Industry Standards

• The FDA's requirement for a prospective, randomized, double-blind, sham surgery-controlled study for AMT-130 aligns with industry standards for pivotal trials in neurodegenerative diseases, such as those conducted by companies like Biogen (e.g., for Aduhelm) or Roche (e.g., for Ocrevus in MS, though not gene therapy).
• The statistically significant slowing of disease progression observed with AMT-130 (75% on cUHDRS) is a strong signal, but the FDA's insistence on a new trial indicates that natural history data or single-arm studies, while informative, are often insufficient for primary efficacy evidence for novel therapies.
• The discontinuation of AMT-162 due to dose-limiting toxicity is a risk inherent in gene therapy development, where novel delivery mechanisms and payloads can present unforeseen safety challenges, a situation seen across the industry with various gene therapy candidates.
• The positive preliminary data for AMT-191, including patient withdrawal from ERT and durable enzyme activity, is promising and aligns with the goals of gene replacement therapies aiming for long-term efficacy, a benchmark for success in rare genetic diseases.

Legal Proceedings

• A class action complaint was filed on February 10, 2026, in the U.S. District Court for the Southern District of New York, alleging false and misleading statements and omissions related to the AMT-130 Phase I/II study and potential BLA filing timing.

Stakeholder Impact

• Shareholders: The FDA's decision on AMT-130 is a significant negative development that could impact share price, requiring a new, costly clinical trial and delaying potential revenue. The class action lawsuit also poses a risk.
• Employees: The discontinuation of the AMT-162 program may impact morale and resource allocation. Increased SG&A expenses suggest investment in growth, potentially including headcount.
• Partners (CSL Behring, Genezen): The termination of supply agreements related to HEMGENIX marks a transition, with Genezen becoming CSL Behring's direct CMO.
• Creditors: The company's strong cash position and projected runway provide some comfort, but the need for future financing and potential delays in revenue generation remain factors.

Next Steps

• Continue engaging with the FDA regarding AMT-130 and conduct a Type B meeting in Q2 2026.
• Submit a UK Marketing Authorization Application for AMT-130 in Q3 2026.
• Continue collecting safety data from patients dosed in the discontinued AMT-162 program.
• Complete contractually specified batch supplies for HEMGENIX to CSL Behring, expected in mid-2026.
• Advance the development of AMT-191 for Fabry disease, pending further evaluation of liver enzyme elevations.

Key Dates

Recommendation

While the FDA's feedback on AMT-130 is a significant negative, the company retains a strong cash position, positive data for AMT-130 in terms of efficacy signals, and progress in other programs like AMT-191. The need for a new, large-scale trial for AMT-130 introduces substantial risk and delay, but the potential for future success remains. The discontinuation of AMT-162 is a setback, but not a deal-breaker for the company's overall prospects. Given the mixed signals, a 'hold' recommendation is appropriate, pending further clarity on the path forward for AMT-130 and the outcomes of ongoing trials.

Keywords

uniQure, gene therapy, Huntington's disease, AMT-130, FDA, BLA, clinical trials, Fabry disease, AMT-191, ALS, AMT-162, HEMGENIX, CSL Behring, financial results, Q1 2026